Drug firm Divi's Laboratories today said its Vishakhapatnam facility has successfully completed inspection by the health products regulators of Ireland and Slovenia without any critical observations.
In a regulatory filing to the BSE, Divi's Laboratories said the company's Unit-2 at Vishakhapatnam has been inspected by five inspectors from Health Products Regulatory Authority (HPRA) of Ireland and Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP) of Slovenia from July 31 to August 4, 2017.
The inspection was focused on follow up on the effectiveness of the corrective and preventive actions (CAPA's) implemented from the last JAZMP inspection, it added.
The inspectors also focused on the general GMP inspection of the site, Divi's Laboratories said.
"The inspection has concluded successfully with no critical observations", it added.
Shares of Divi's Laboratories were today trading at Rs 680.10 per scrip in the afternoon trade on BSE, up 1.44 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
